FDA approves new pancreatic cancer therapy demonstrating significant survival extension

The FDA has granted approval for a new pancreatic cancer treatment that nearly doubled overall survival rates in clinical trials. This development marks a potential shift in standard-of-care protocols for a highly lethal malignancy, though long-term real-world efficacy remains to be observed.